Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment

作者：Wu, Jian; Shen, Jiawei; Han, Ying; Qiao, Qinghua; Dai, Wei; He, Bangshun; Pang, Rongrong; Zhao, Jun; Luo, Tao; Guo, Yanju; Yang, Yang; Wu, Qiuyue; Jiang, Weijun; Zhang, Jing; Zhang, Mingchao; Li, Na; Li, Weiwei; Xia, Xinyi^*

来源：Frontiers in Immunology, 2021, 12: 598799.

DOI：10.3389/fimmu.2021.598799

• SARS-CoV-2
• COVID-19
• IL6
• tocilizumab
• CPT
• discharge

A comprehensive understanding of the dynamic changes in interleukin-6 (IL-6) levels is essential for monitoring and treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). By analyzing the correlations between IL-6 levels and health conditions, underlying diseases, several key laboratory detection indices, and the prognosis of 1,473 patients with the coronavirus disease 2019 (COVID-19), the role of IL-6 during SARS-CoV-2 infection was demonstrated. Our results indicated that IL-6 levels were closely related to age, sex, body temperature, oxygen saturation (SpO(2)) of blood, and underlying diseases. As a stable indicator, the changes in IL-6 levels could indicate the inflammatory conditions during a viral infection. Two specific treatments, namely, tocilizumab and convalescent plasma therapy (CPT), decreased the level of IL-6 and relieved inflammation. CPT has an important role in the therapy for patients with critical COVID-19. We also found that patients with IL-6 levels, which were 30-fold higher than the normal level, had a poor prognosis compared to patients with lower levels of IL-6.

• 单位
  南京大学; 1; 南方医科大学